Brief: Equillium Announces Initiation Of Phase 3 Equator Study Of Itolizumab In First-Line Acute Graft-Versus-Host Disease
04/03/2022 13:29
March 4 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES INITIATION OF THE PHASE 3 EQUATOR
STUDY OF
ITOLIZUMAB IN FIRST-LINE ACUTE GRAFT-VERSUS-HOST DISEASE
Source text for Eikon: ID:nBw3r8Cbza
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations